The increasing incidence of infections by carbapenem-resistant enterobacteria (CRE), in particular carbapenem-resistant Klebsiella pneumoniae (CRKp), is a significant public health challenge worldwide.1 The interim results of the last European survey on CRE (EuSCAPE project 2013) indicate that CRKp is endemic in Italy, and that this endemicity is mostly contributed to by strains producing KPC-type carbapenemases.
CRKp infections are associated with high morbidity and mortality rates, particularly among Intensive Care Units (ICU) patients, recipients of solid organ transplants (SOT) and patients with hematological malignancies.31 The Gruppo Italiano Trapianto Midollo Osseo (GITMO) recently performed a retrospective study (2010–2013) which involved 52 stem cell transplant (SCT) centers to assess the epidemiology and the prognostic factors of CRKp infections in autologous and allogeneic SCT.4 Cases of CRKp infection were reported in 53.4% of the centers and were documented in 0.4% of autologous and 2% of allogeneic SCTs. A CRKp colonization was followed by an infection in about 30% of cases. The infection-related mortality rate was 16% in autologous and 64.4% in allogeneic SCT. A pre-transplant CRKp infection and inadequate first-line treatment were independent factors associated with an increase in mortality in allogeneic SCT patients who developed a CRKp infection. Indeed, despite the administration of a first-line CRKp-targeted antibiotic therapy (CTAT) (see below), 55% of patients who received a CTAT still died. These data underscored the challenge regarding CRKp infections, particularly in the allogeneic-SCT setting, in terms of outcome and management of post-transplant complications, and also raised an issue about the eligibility for transplant among patients who got colonized or had developed a CRKp infection before transplant.
Based on these original data and on the recent literature, a multidisciplinary group of experts from GITMO, the Italian Association of Clinical Microbiologists (Associazione Microbiologi Clinici Italiani; AMCLI), the Italian Society of Infectious and Tropical Diseases (Società Italiana Malattie Infettive e Tropicali; SIMIT), and the Italian National Transplant Center (Centro Nazionale Trapianti; CNT) was convened with the aim of providing consensus recommendations for the management of CRKp infection/colonization in autologous and allogeneic-SCT recipients.
The Expert Panel (EP) included 17 specialists in hematology, infectious diseases, clinical microbiology and nursing, who were selected by virtue of their expertise in research and clinical practice of infections in SCT. The areas of major concern were defined by generating clinical key issues using the criterion of clinical relevance, i.e. impact on patient management and risk of inappropriateness, and recommendations were obtained according to a nominal group technique.
The EP focused its discussion on four key-issues considered relevant for the present recommendations that are shown in Table 1.
Table 1.Recommendations for the management of carbapenem-resistant Klebsiella pneumoniae (CRKp) infections in stem cell transplant recipients.*
References
- Munoz-Price LS, Poirel L, Bonomo RA. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013; 13(9):785-796. PubMedhttps://doi.org/10.1016/S1473-3099(13)70190-7Google Scholar
- Satlin MJ, Jenkins SG, Walsh TJ. The Global Challenge of Carbapenem-Resistant Enterobacteriaceae in Transplant Recipients and Patients With Hematologic Malignancies. Clin Infect Dis. 2014; 58(9):1274-1283. PubMedhttps://doi.org/10.1093/cid/ciu052Google Scholar
- Pagano L, Caira M, Trecarichi EM. Carbapenemase-producing Klebsiella pneumoniae and hematologic malignancies. Emerg Infect Dis. 2014; 20(7):1235-1236. PubMedhttps://doi.org/10.3201/eid2007.130094Google Scholar
- Girmenia C, Rossolini GM, Piciocchi A. Infections by carbapenem-resistant Klebsiella pneumoniae in stem cell transplant recipients: a nationwide retrospective survey from Italy. Bone Marrow Transplant. 2015; 50(2):282-288. PubMedhttps://doi.org/10.1038/bmt.2014.231Google Scholar
- Zuckerman T, Benyamini N, Sprecher H. SCT in patients with carbapenem resistant Klebsiella pneumoniae: a single center experience with oral gentamicin for the eradication of carrier state. Bone Marrow Transplant. 2011; 46(9):1226-1230. PubMedhttps://doi.org/10.1038/bmt.2010.279Google Scholar
- Tascini C, Sbrana F, Flammini S. Oral gentamicin gut decontamination for prevention of KPC-producing Klebsiella pneumoniae infections: the relevance of concomitant systemic antibiotic therapy. Antimicrob Agents Chemother. 2014; 58(4):1972-1976. PubMedhttps://doi.org/10.1128/AAC.02283-13Google Scholar
- Bartoletti M, Lewis RE, Tumietto F.Paper presented at: ; Google Scholar
- Giannella M, Trecarichi EM, De Rosa FG. Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study. Clin Microbiol Infect. 2014; 20(12):1357-1362. PubMedhttps://doi.org/10.1111/1469-0691.12747Google Scholar
- Schwaber MJ, Lev B, Israeli A. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis. 2011; 52(7):848-855. PubMedhttps://doi.org/10.1093/cid/cir025Google Scholar
- Fournier S, Monteil C, Lepainteur M. Long-term control of carbapenemase-producing Enterobacteriaceae at the scale of a large French multihospital institution: a nine-year experience, France, 2004 to 2012. Euro Surveill. 2014; 19(19):20802. PubMedGoogle Scholar
- Averbuch D, Orasch C, Cordonnier C. Haematologica. 2013; 98(12):1826-1835. PubMedhttps://doi.org/10.3324/haematol.2013.091025Google Scholar
- Averbuch D, Cordonnier C, Livermore DM. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica. 2013; 98(12):1836-1847. PubMedhttps://doi.org/10.3324/haematol.2013.091330Google Scholar
- Saidel-Odes L, Polachek H, Peled N. A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriage. Infect Control Hosp Epidemiol. 2012; 33(1):14-19. PubMedhttps://doi.org/10.1086/663206Google Scholar
- Lübbert C, Faucheux S, Becker-Rux D. Rapid emergence of secondary resistance to gentamicin and colistin following selective digestive decontamination in patients with KPC-2-producing Klebsiella pneumoniae: a single-centre experience. Int J Antimicrob Agents. 2013; 42(6):565-570. PubMedhttps://doi.org/10.1016/j.ijantimicag.2013.08.008Google Scholar
- Oren I, Sprecher H, Finkelstein R. Eradication of carbapenem-resistant Enterobacteriaceae gastrointestinal colonization with non-absorbable oral antibiotic treatment: A prospective controlled trial. Am J Infect Control. 2013; 41(12):1167-1172. PubMedhttps://doi.org/10.1016/j.ajic.2013.04.018Google Scholar